02.01.2019 11:11:03
|
What Awaits Sesen Bio Tomorrow (Jan.3)?
(RTTNews) - Shares of Sesen Bio Inc. (SESN) have gained nearly 48% over the last 5 trading days, as the Company gears up for updated data from its VISTA trial.
VISTA is a phase III trial of investigational drug Vicinium in patients with high-grade non-muscle invasive bladder cancer who have previously received two courses of bacillus Calmette-Guérin (BCG), the standard of care, and whose disease is BCG-unresponsive.
The trial involves 133 patients and 3 Cohorts.
On May 21, 2018, the Company reported encouraging three-month data from its VISTA trial, with Vicinium treatment demonstrating a complete response rate of 42 percent at three months. However, despite the encouraging data, Sesen shares tumbled 23% that day as investors were spooked by 4 treatment-related serious adverse events that were reported in the trial, including acute kidney injury or renal failure and cholestatic hepatitis.
The six-month data from the VISTA study is slated to be announced tomorrow, Thursday, January 3, 2019, at 8:30 a.m. ET.
The twelve-month data from the trial are anticipated in mid-2019.
SESN has traded in a range of $0.76 to $3.50 in the last 1 year. The stock closed Monday's (Dec.31, 2018) trading at $1.42, unchanged from the previous day's close.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eleven Biotherapeutics Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |